Long-term BCG immune therapy of superficial bladder tumours.
Long-term local BCG treatment of superficial bladder tumours is described and the 5-year results are reviewed. Complications of major significance in the course of immune therapy did not occur, loss due to death was not recorded. PPD skin test failed to furnish extra information regarding the biologic behaviour of the tumour. Annual repeats of the therapy promise better results than one single 6-week course.
Somogyi
L
L
Department of Urology, University Medical School, Pécs, Hungary.
Szántó
A
A
Polyák
L
L
Baranyay
F
F
Drinóczy
M
M
D000283:Administration, Intravesical; D001500:BCG Vaccine / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000453:epidemiology / Q000628:therapy*; D004334:Drug Administration Schedule; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology*; D013997:Time Factors; D014374:Tuberculin Test; D001749:Urinary Bladder Neoplasms / Q000453:epidemiology / Q000628:therapy*
D001500:BCG Vaccine